187 Efficacy and safety of 22 weeks of maintenance therapy with peginterferon alfa-2A (40KD) (PEGASYS™) alone versus peginterferon alfa-2A (40KD) plus ribavirin(COPEGUS™) in naive patients with chronic hepatitis C and genotype 1 who responded to a 24-week course of peginterferon alfa-2A (40KD) plus ribavirin: an open, multicenter, randomized trial
- 31 December 2003
- journal article
- abstracts
- Published by Elsevier in Hepatology
- Vol. 38, 244-245
- https://doi.org/10.1016/s0270-9139(03)80230-6
Abstract
No abstract availableKeywords
This publication has 0 references indexed in Scilit: